Robeco Institutional Asset Management B.V. Buys New Position in PerkinElmer, Inc. (NYSE:PKI)

Robeco Institutional Asset Management B.V. purchased a new position in shares of PerkinElmer, Inc. (NYSE:PKI) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 5,842 shares of the medical research company’s stock, valued at approximately $563,000.

Several other institutional investors have also bought and sold shares of the business. Geode Capital Management LLC boosted its holdings in shares of PerkinElmer by 8.9% during the 4th quarter. Geode Capital Management LLC now owns 1,522,499 shares of the medical research company’s stock worth $119,450,000 after buying an additional 124,168 shares in the last quarter. FMR LLC boosted its holdings in shares of PerkinElmer by 0.8% during the 1st quarter. FMR LLC now owns 1,233,993 shares of the medical research company’s stock worth $118,907,000 after buying an additional 10,020 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of PerkinElmer by 1.2% during the 1st quarter. Northern Trust Corp now owns 1,082,136 shares of the medical research company’s stock worth $104,274,000 after buying an additional 13,212 shares in the last quarter. Artisan Partners Limited Partnership boosted its holdings in shares of PerkinElmer by 42.3% during the 1st quarter. Artisan Partners Limited Partnership now owns 408,941 shares of the medical research company’s stock worth $39,406,000 after buying an additional 121,552 shares in the last quarter. Finally, Parametric Portfolio Associates LLC boosted its holdings in shares of PerkinElmer by 3.7% during the 1st quarter. Parametric Portfolio Associates LLC now owns 277,267 shares of the medical research company’s stock worth $26,717,000 after buying an additional 9,985 shares in the last quarter. Hedge funds and other institutional investors own 95.99% of the company’s stock.

Shares of NYSE:PKI traded down $1.02 during trading on Friday, reaching $83.08. 7,679 shares of the stock were exchanged, compared to its average volume of 752,395. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.25 and a current ratio of 1.82. PerkinElmer, Inc. has a 1-year low of $71.83 and a 1-year high of $103.00. The stock has a fifty day moving average price of $93.42. The stock has a market capitalization of $9.18 billion, a price-to-earnings ratio of 23.01, a price-to-earnings-growth ratio of 1.47 and a beta of 1.25.

PerkinElmer (NYSE:PKI) last issued its earnings results on Monday, July 29th. The medical research company reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.01 by ($0.01). PerkinElmer had a return on equity of 16.07% and a net margin of 9.01%. The firm had revenue of $722.50 million for the quarter, compared to analyst estimates of $729.10 million. During the same period in the previous year, the company earned $0.91 earnings per share. PerkinElmer’s revenue for the quarter was up 2.7% compared to the same quarter last year. Equities analysts anticipate that PerkinElmer, Inc. will post 4.04 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, November 8th. Stockholders of record on Friday, October 18th will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.34%. The ex-dividend date of this dividend is Thursday, October 17th. PerkinElmer’s payout ratio is 7.76%.

A number of equities analysts have issued reports on PKI shares. Raymond James started coverage on PerkinElmer in a report on Wednesday, July 10th. They set an “outperform” rating on the stock. Royal Bank of Canada restated a “hold” rating and set a $41.00 price target on shares of PerkinElmer in a report on Friday, May 3rd. UBS Group increased their price target on PerkinElmer from $99.00 to $101.00 and gave the stock a “neutral” rating in a report on Tuesday, July 30th. Wolfe Research started coverage on PerkinElmer in a report on Thursday, May 30th. They set a “peer perform” rating on the stock. Finally, Zacks Investment Research upgraded PerkinElmer from a “hold” rating to a “buy” rating and set a $89.00 price target on the stock in a report on Thursday, May 30th. Eleven equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $78.58.

PerkinElmer Company Profile

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.

Featured Story: Dividend Achievers

Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.